Company intelligence / Profile preview
Abliva AB
Lund, Sweden
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Abliva (formerly NeuroVive) is focused on developing treatments for primary mitochondrial diseases. The company has one project in clinical phase I (KL1333) for chronic treatment of genetic mitochondrial diseases and has completed early Phase 2 studies for NeuroSTAT for traumatic brain injury.
- Therapeutic areas
- GastroenterologyRare DiseasesNeurologyCardiovascular
- Modalities
- Small moleculesCyclosporine-based compounds
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
Yungjin Pharm CorpSihuan Pharmaceuticalto-BBBSelcia Limited
Beyond the preview
Go deeper on Abliva AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abliva AB.